Vifor Pharma reports sustained growth in 2021 : vimarsana.co

Vifor Pharma reports sustained growth in 2021 Ad hoc announcement pursuant to Art. 53 LR Net sales up 4.0% and EBITDA up 6.6% at constant exchange rates (CER) a result of profitable growth in net sales combined with diligent cost containment Iron franchise – Ferinject® / Injectafer® sales up...

Related Keywords

Germany , Australia , Fribourg , Switzerland , Japan , Quettingen , Switzerland General , United States , Lisbon , Lisboa , Portugal , New Zealand , Singapore , Canada , American , Vifor Pharma , Abbas Hussain , Angion Biomedica , Oliverp Kronenberg , Alexandros Sigalas , American College Of Cardiology , Sandoz Inc , Drug Administration , Mylan Laboratories Ltd , Vifor Pharma Executive Committee , European Society Of Cardiology , Vifor Pharma Group , European Medicines Agency , Us Centers For Medicare Medicaid Services , Chief Executive Officer , European Society , American Regent , New Drug Application , Abbreviated New Drug Application , Erythropoiesis Stimulating Agent , Chronic Kidney Disease , Akebia Therapeutics , Prescription Drug User Fee Act , Transitional Drug Add On Payment Adjustment , Medicaid Services , Authorization Application , Sanifit Therapeutics , Peripheral Artery Disease , American College , Annual Scientific Session , Travere Therapeutics , Aortic Valve Stenosis , Chief Commercial Officer , Chief Financial Officer Alexandros Sigalas , Group General Counsel ,